Merav Leiba - Concepedia

Author

Merav Leiba

Sheba Medical Center ORCID

Also Known As

Kenshi Suzuki, M Leiba, M. Leiba, MERAV LEIBA, Merav Leiba

143

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Sheba Medical Center Tel Aviv University Ben-Gurion University of the Negev National and Kapodistrian University of Athens Harvard University

About

Merav Leiba is an author at Sheba Medical Center specializing in medicine, pathology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	371
2	Health Sciences	4	4	111
3	Cell Biology	2	2	52
4	Public Health	1	1	23
5	Allergy	1	1	41

Merav Leiba

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies Raanan Berger, Rinat Rotem‐Yehudar, Gideon Slama, Clinical Cancer Research	2008	692
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu Yu‐Tzu Tai, Myles Dillon, Weihua Song, Blood	2007	467
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study Nizar J. Bahlis, Meletios Α. Dimopoulos, Darrell White, Leukemia	2020	231
Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX Meletios Α. Dimopoulos, Jesús F. San Miguel, Andrew R. Belch, Haematologica	2018	207
Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype Katia Beider, Hanna Bitner, Merav Leiba, Oncotarget	2014	158
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications Jana Jakubı́ková, Sophia Adamia, Maria Kost‐Alimova, Blood	2011	153
Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease Merav Leiba Annals of the Rheumatic Diseases	2004	119
RETRACTED: Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis Yu‐Tzu Tai, Mariateresa Fulciniti, Teru Hideshima, Blood	2007	109
Cytogenetics of extramedullary manifestations in multiple myeloma Lisa Billecke, Eva Maria Murga Penas, Annette M. May, British Journal of Haematology	2013	99
Common FMF alleles may predispose to development of Behcet's disease with increased risk for venous thrombosis E. Rabinovich, Yael Shinar, Merav Leiba, Scandinavian Journal of Rheumatology	2007	86

Page 1